GENFIT : Extra-financial Performance - 2020 Statement

Extra-financial Performance 2020 Statement

Publication: June 30, 2021

We are a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs.

GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades.

We are dedicated to improving the lives of patients who are at the center of our mission and our goal is to offer robust and secure solutions tailored to their needs. Our translational disease driven approach is the strength of our R&D.

We believe in a full comprehension of a disease to discover

therapeutic and diagnostic solutions.

About GENFIT

3

• Capitalizing on Our Scientific and Clinical Expertise
• Targeting Diseases with High Unmet Medical Needs
• Developing a Competitive Market-Access Strategy

Presentation of our CSR Strategy and Values	4
Business Model and Value Distribution	6
Employee Relations	7

• Recruitement
• Employment
• Social relations
• Working Environment
• Health and safety at work
• Gender equality
• Training
• Compensation

Societal Issues

11

• Territorial, economic and social impact of the Company's activity
• Relationships with persons or organizations interested in the Company's activity
• Subcontractors and Providers

Corruption and Human Rights Issues

13

• Loyalty and Code of Ethics
• Human Rights

Environmental Issues

14

• General policy on hygiene, health, safety, and environment
• Pollution
• Sustainable use of resources
• Circular economy
• Climate change

Methodology

17

• Reporting scope
• Methodological specificity

About GENFIT

GENFIT is a late-stage biopharmaceutical patients with metabolic and chronic liver

Capitalizing on Our Scientific and Clinical Expertise

Our translational disease-driven research approach is based on strong expertise, featuring in-house knowledge of drug and diagnostic design and development. A pioneer in the field of nuclear receptor-based drug discovery, GENFIT has a rich history and strong scientific heritage spanning more than two decades.

This approach, along with our strong bioinformatics capabilities, enables us to discover and develop drug candidates and diagnostic technologies. Professor Bart Staels, a world-renowned expert in nuclear receptors, co-founded GENFIT, and has played a key role in shaping our company's expertise over the years. Today, he is chair of the Scientific Advisory Board, lending his unique experience and essential know-how, and supporting our role as an innovative leader in the discovery of solutions for the field.

Targeting Diseases with High Unmet Medical Needs

We are committed to improving outcomes for patients with unmet medical needs, focusing on liver and metabolic diseases with limited treatment options.

We are exploring elafibanor as a potential candidate for the treatment of primary biliary cholangitis (PBC), a chronic disease in which bile ducts in the liver are gradually destroyed. The damage to bile ducts can inhibit the liver's ability to rid the body of toxins, and may lead to cirrhosis. In December 2018, we announced positive results from our Phase 2 clinical trial evaluating elafibranor for the treatment of PBC. Elafibranor was then granted Breakthrough Therapy Designation by the FDA. A Phase 3 pivotal trial, ELATIVE™, is currently enrolling.

A clinical program has been launched in Acute on Chronic Liver Failure (ACLF) : a syndrome in patients with chronic liver disease and cirrhosis characterized by acute hepatic decompensation resulting in liver failure and/or one or more extrahepatic organ failures. It is associated with increased risk for short- term mortality. There are no approved drugs to treat

patients and therefore a need exists for a therapy that helps them to survive without transplantation.

We also have a long experience in nonalcoholic steatohepatitis, or NASH. NASH is a chronic, potentially progressive, liver disease impacting millions of people worldwide and is the most severe form of nonalcoholic fatty liver disease (NAFLD). NASH disease activity is characterized by fat accumulation, inflammation, and injury of the liver-increasing the risk of fibrosis or scarring. The disease carries no obvious symptoms in its early stages and lacks widely available non-invasive tests specifically developed for diagnosis. As a result, NASH remains largely underdiagnosed, despite severely impacting the health and function of the liver.

We have designed a novel diagnostic technology to improve early diagnosis of this disease, and developed NIS4™, a proprietary GENFIT-developed technology. NIS4™ underlies a novel, non-invasive,blood-based molecular biomarker test intended to identify at-risk NASH (NAFLD Activity Score ≥4 and Fibrosis stage ≥2) in patients with metabolic risk factors.

Developing a Competitive Market-Access Strategy

GENFIT's clinical experience provides us with a solid foundation and supports our long-term objective of becoming a commercial company. We intend to build upon our pioneer approach and leadership in NASH diagnostics to achieve our goal of bringing our diagnostic technology to patients in need. We also intend to bring our drug candidates to patients in need in the field of specialty care indications and orphan diseases, such as PBC and ACLF.

Our foremost goal is to contribute to worldwide health innovation by addressing unmet medical needs in cholestatic and chronic metabolic liver diseases.

3

Presentation of our CSR Strategy and Values

Our mission is to deliver therapeutic and diagnostic solutions designed to meet the unmet medical needs of millions of patients around the world.

Collaboration

Integrity

We deliver true and accurate information to our partners and stakeholders and build our business relationships with honesty and transparency.

We demand of ourselves and others the highest ethical standards and we conduct

Our activity, by nature located at the heart of major strategic public health is- sues, therefore has an intrinsically societal dimension, and our vocation is to serve most of our fellow citizens.

Leader in the field of nuclear receptors, and enjoying a strong and internationally recognized scientific heritage, our ambition is to bring hope to millions

Innovation

We pioneer new approaches and innovative technologies to

We bring together talented employees with unique perspectives and experiences and recognize and value diversity as a source of strength. We ensure that all employees and stakeholders are treated equally with dignity and respect.

We strive to create value and ensure that our success relies on working with others across industries and geographies.

our business in a socially and environmentally sustainable manner.

of patients suffering from chronic and potentially serious pathologies such as cholestatic diseases (including PBC, PSC and other rare cholestatic pediatric diseases), ACLF (Acute on Chronic Liver Failure) and NASH (Non-alcoholic steatohepatitis, a metabolic liver disease). This hope is fueled today by many results obtained over several years in terms of treatment and diagnosis.

Patient centric

We are deeply committed to improving the health and quality of life of patients affected by cholestatic and chronic metabolic liver diseases.

We seek new ways to advance science and medicine, with the goal of optimizing care for patients with unmet medical needs.

contribute to, and to advance quality solutions in patient care. We adapt ourselves and persevere in looking for efficiency and success in developing and bringing to the market first or best-in-class diagnostic and therapeutic solutions for patients.

Our core values are the beliefs, philosophies, and principles that drive our business. They impact the experiences of our employees, as well as the relationships we develop with our community, customers, partners, and shareholders.

4

Every day, our employees use their skills and experience at the service of GENFIT, with the aim of actively contributing to the success of the company's mission. Established in France and the United States, GENFIT is committed to maintaining a high level of flexibility. This agility characterizes us ans is fully part of our company culture.

Committed to environmental and social responsibilities since our creation, we wanted to highlight more explicitly the CSR principles that guide our actions and help structure our deployment, and apply these in the collaboration with our partners:

Employee Relations - at the		Societal Issues -		Corruption		Environmental
service of the Individual		at the service of Civil Society		and Human Rights		Issues

• Improving and maintaining the well- being of our employees
• Guaranteeing equality and equity in terms of working conditions, compensation or access to training for both women and men and regardless of academic or professional profile
• Guaranteeing the diversity of profiles and skills

• Contributing through our activities to the health of our fellow citizens
• Forging links with local institutions and businesses (local institutions located in "Eurasanté" parc and "Nutrition Santé Longévité" cluster, schools, universities, etc.), and national/international associations (Patients associations: Global Liver Institute, American Liver Foundation, Swiss NASH Foundation, SOS Hépatities, etc.) whether public or private
• Maintaining good relations with our subcontractors and partners, in an ethical spirit and adopting a fair sense of business

• Ensuring complete integrity and	• Ensuring full compliance with
overall transparency in our activities	health, safety, and security
and relationships, while respecting	standards
business confidentiality	• Managing and reducing our
• Ensuring respect for human	environmental footprint
rights within GENFIT and, as far as	• Using our resources to
possible, with our subcontractors	minimize the impact of our
and partners	activity

More details p.7

More details p.11

More details p.13

More details p.14

5